Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion-Reference-Cited by-同舟云学术

Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion

Published:2018-08-17 Issue:4 Volume:1 Page:e181588
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Saloner Brendan¹,Levin Jonathan¹,Chang Hsien-Yen¹²,Jones Christopher³,Alexander G. Caleb²⁴⁵

Affiliation:

1. Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

2. Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

3. National Mental Health and Substance Use Policy Laboratory, Substance Abuse and Mental Health Services Administration, US Department of Health and Human Services, Washington, DC

4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

5. Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

http:///jamanetworkopen/article-pdf/1/4/e181588/17309610/saloner_2018_oi_180099.pdf

Reference35 articles.

1. Drug overdose deaths in the United States, 1999-2016.;Hedegaard;NCHS Data Brief,2017

2. Impact of Medicaid Expansion on access to opioid analgesic medications and medication-assisted treatment.;Sharp;Am J Public Health,2018

3. Moving beyond parity—mental health and addiction care under the ACA.;Barry;N Engl J Med,2011

4. Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004-2013.;Saloner;JAMA,2015

5. Buprenorphine-naloxone therapy in pain management.;Chen;Anesthesiology,2014

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. State‐level racial and ethnic disparities in buprenorphine treatment duration in the United States;The American Journal on Addictions;2024-08-06

2. Medicaid expansion and opioid prescriptions: Evidence from the Medical Expenditure Panel Survey;Health Economics;2024-08-05

3. Federal Impacts on Buprenorphine Prescribing in Washington State, 2012 to 2022;American Journal of Public Health;2024-07

4. State-level factors associated with implementation of prescription drug monitoring program integration and mandatory use policies, United States, 2009–2020;Journal of the American Medical Informatics Association;2024-06-21

5. Medicaid for Medical-Correctional Care: Time to Manage What is Reimbursed;Journal of General Internal Medicine;2024-06-03